Phase II/III proof-of-concept trial investigating the effectiveness and safety of eprodisate to treat certain medical manifestations of sarcoidosis

Trial Profile

Phase II/III proof-of-concept trial investigating the effectiveness and safety of eprodisate to treat certain medical manifestations of sarcoidosis

Planning
Phase of Trial: Phase II/III

Latest Information Update: 12 Nov 2015

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Pulmonary sarcoidosis; Sarcoidosis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Nov 2015 According to BELLUS Health media release, an investigational new drug application (IND) is expected to be filled with the U.S. FDA in the first half of 2016.
    • 25 Feb 2015 According to a Bellus Health media release, this trial is expected to begin in mid-2015.
    • 25 Feb 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jul 2015 according to a Bellus Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top